Recently, it was demonstrated that the RNA binding protein MEX3B is linked with resistance to cancer immunotherapy in melanoma patients, by binding and destabilizing the HLA-A mRNA resulting in decreased HLA-A expression on the surface of tumor cells and thereby protecting the tumor cells by T cell-mediated recognition and elimination [130]. This evidence concerns the gene MEX3B and neoplasm.